ATOSSA THERAPEUTICS, INC.
ATOS · XNASCIK 1488039fmd_1RVX4BFCWVZQ5XFGGQTP56ZN23制造业 · 医药制剂模板: 标准
覆盖范围: 2010年1月01日 至 2026年9月30日，共 62 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | – | – | – | – | – | – | – | – | – | – |
| 营业成本 | – | – | – | – | – | – | – | – | – | – |
| 毛利润 | – | – | – | – | – | – | – | – | – | – |
| 研发费用 | 1 | 2 | 4 | 7 | 7 | 9 | 15 | 17 | 14 | 21 |
| 营业费用合计 | 8 | 8 | 11 | 17 | 15 | 21 | 28 | 31 | 28 | 37 |
| 营业利润 | (8) | (8) | (11) | (17) | (15) | (21) | (28) | (31) | (28) | (37) |
| 利息费用 | – | – | – | – | – | – | – | – | – | – |
| 利息及投资收益 | – | – | – | – | – | 0 | 1 | 4 | 4 | 2 |
| 其他营业外收入（支出） | 2 | 0 | 0 | 0 | 0 | (0) | (0) | (0) | (0) | (0) |
| 税前利润 | (6) | (8) | (11) | (17) | (18) | (21) | (27) | (30) | (26) | (35) |
| 所得税费用 | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 持续经营净利润 | (6) | (8) | (11) | (17) | (18) | (21) | (27) | (30) | (26) | (35) |
| 净利润 | (6) | (8) | (11) | (17) | (18) | (21) | (27) | (30) | (26) | (35) |
| 归属于普通股股东的净利润 | (6) | (11) | (23) | (17) | (22) | (21) | – | – | – | – |